Richard C. Gregory

1.9k total citations
34 papers, 1.5k citations indexed

About

Richard C. Gregory is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Richard C. Gregory has authored 34 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Immunology and 12 papers in Molecular Biology. Recurrent topics in Richard C. Gregory's work include Cancer Immunotherapy and Biomarkers (11 papers), interferon and immune responses (8 papers) and Cytokine Signaling Pathways and Interactions (7 papers). Richard C. Gregory is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), interferon and immune responses (8 papers) and Cytokine Signaling Pathways and Interactions (7 papers). Richard C. Gregory collaborates with scholars based in United States, France and Japan. Richard C. Gregory's co-authors include Toshiyasu Taniguchi, Alan D. D’Andrea, Paul R. Andreassen, Irene García-Higuera, Markus Grompe, Don M. Wojchowski, William S. Lane, Bo Xu, Seong‐Tae Kim and Michael B. Kastan and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Blood.

In The Last Decade

Richard C. Gregory

32 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard C. Gregory United States 15 1.1k 422 408 187 183 34 1.5k
Leandros-Vassilios Vassiliou United Kingdom 3 1.4k 1.3× 734 1.7× 297 0.7× 98 0.5× 180 1.0× 4 1.6k
Hena R. Ashar United States 12 1.2k 1.1× 522 1.2× 380 0.9× 118 0.6× 177 1.0× 13 1.6k
Louise J. Barber United Kingdom 20 1.7k 1.6× 690 1.6× 499 1.2× 124 0.7× 270 1.5× 29 2.1k
Haihui Lu United States 17 1.6k 1.5× 793 1.9× 355 0.9× 370 2.0× 152 0.8× 27 2.1k
Jonathan Grim United States 8 1.7k 1.6× 766 1.8× 212 0.5× 168 0.9× 160 0.9× 9 2.1k
Sara Widaa United Kingdom 3 762 0.7× 354 0.8× 632 1.5× 115 0.6× 266 1.5× 3 1.3k
Nadya Dimitrova United States 15 1.6k 1.5× 267 0.6× 784 1.9× 82 0.4× 71 0.4× 20 1.8k
Andrea Krempler Germany 12 1.8k 1.7× 914 2.2× 520 1.3× 131 0.7× 136 0.7× 19 2.2k
Josephine Mun Yee Ko Hong Kong 24 831 0.8× 491 1.2× 443 1.1× 127 0.7× 102 0.6× 63 1.4k
Alex C. Minella United States 20 929 0.9× 636 1.5× 244 0.6× 255 1.4× 89 0.5× 35 1.4k

Countries citing papers authored by Richard C. Gregory

Since Specialization
Citations

This map shows the geographic impact of Richard C. Gregory's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Gregory with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Gregory more than expected).

Fields of papers citing papers by Richard C. Gregory

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Gregory. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Gregory. The network helps show where Richard C. Gregory may publish in the future.

Co-authorship network of co-authors of Richard C. Gregory

This figure shows the co-authorship network connecting the top 25 collaborators of Richard C. Gregory. A scholar is included among the top collaborators of Richard C. Gregory based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard C. Gregory. Richard C. Gregory is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Porciuncula, Angelo, Vicky A. Appleman, Richard C. Gregory, et al.. (2024). Abstract 6732: Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancer. Cancer Research. 84(6_Supplement). 6732–6732. 1 indexed citations
3.
Rajasekaran, Karthik, Thomas J. Ow, Cherie‐Ann O. Nathan, et al.. (2023). Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.. Journal of Clinical Oncology. 41(16_suppl). 2579–2579. 2 indexed citations
4.
Pratz, Keith W., Jason Kaplan, Moshe Levy, et al.. (2022). A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 108(3). 705–716. 10 indexed citations
5.
6.
Hatton, Beryl A., Marc Grenley, Sally Ditzler, et al.. (2022). Abstract 620: Intratumoral microdosing via the CIVO® Platform reveals anti-tumor immune responses induced by the STING Agonist TAK-676 alone and in combination with chemotherapies. Cancer Research. 82(12_Supplement). 620–620. 1 indexed citations
7.
Chen, Qing, Diego A. Gianolio, James E. Stefano, et al.. (2019). Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody–drug conjugation. Organic & Biomolecular Chemistry. 17(35). 8115–8124. 14 indexed citations
8.
Chen, Qing, Diego A. Gianolio, James E. Stefano, et al.. (2018). Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High‐Drug‐Load Antibody–Drug Conjugates. ChemMedChem. 13(8). 790–794. 11 indexed citations
9.
He, Timothy, Julie-Ann Gavigan, Stéphanie Vougier, et al.. (2018). A Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors of CD73 with Diverse Inhibition Modalities. SLAS DISCOVERY. 23(3). 264–273. 13 indexed citations
10.
Gregory, Richard C., Rita Greco, Hongjing Qu, et al.. (2018). Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1. Cancer Research. 78(13_Supplement). 2790–2790. 3 indexed citations
11.
Munnink, Thijs H. Oude, Hetty Timmer‐Bosscha, Carolina P. Schröder, et al.. (2011). PET with the89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models. Journal of Nuclear Medicine. 52(12). 2001–2008. 46 indexed citations
12.
Munroe, Kenneth, Jingzang Tao, John M. McPherson, et al.. (2009). Abstract B244: Inhibition of metastases by a neutralizing TGFβ-specific antibody involves the activity of cytotoxic T lymphocytes and natural killer cells. Molecular Cancer Therapeutics. 8(12_Supplement). B244–B244. 1 indexed citations
13.
Fattouh, Ramzi, Katherine Arias, Jill R. Johnson, et al.. (2008). Transforming Growth Factor-β Regulates House Dust Mite–induced Allergic Airway Inflammation but Not Airway Remodeling. American Journal of Respiratory and Critical Care Medicine. 177(6). 593–603. 78 indexed citations
14.
Gregory, Richard C., et al.. (2004). The Dollarization Discipline: How Smart Companies Create Customer Value...and Profit from It. Medical Entomology and Zoology. 5 indexed citations
15.
Taniguchi, Toshiyasu, Irene García-Higuera, Bo Xu, et al.. (2002). Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways. Cell. 109(4). 459–472. 354 indexed citations
16.
Gregory, Richard C., Toshiyasu Taniguchi, & Alan D. D’Andrea. (2002). Regulation of the Fanconi anemia pathway by monoubiquitination. Seminars in Cancer Biology. 13(1). 77–82. 53 indexed citations
17.
Gregory, Richard C., et al.. (2000). SUBTRACTION CLONING AND INITIAL CHARACTERIZATION OF NOVEL EPO-IMMEDIATE RESPONSE GENES. Cytokine. 12(7). 845–857. 23 indexed citations
18.
Gregory, Richard C., Yong Tang, Lan Gao, et al.. (2000). ANTI-GAL ANTIBODIES IN HUMANS AND 1, 3??-GALACTOSYLTRANSFERASE KNOCK-OUT MICE1. Transplantation. 69(12). 2593–2600. 18 indexed citations
19.
Wojchowski, Don M., et al.. (1999). Signal Transduction in the Erythropoietin Receptor System. Experimental Cell Research. 253(1). 143–156. 188 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leandros-Vassilios Vassiliou Breakdown of academic impact, for papers by Hena R. Ashar Breakdown of academic impact, for papers by Louise J. Barber Breakdown of academic impact, for papers by Haihui Lu Breakdown of academic impact, for papers by Jonathan Grim Breakdown of academic impact, for papers by Sara Widaa Breakdown of academic impact, for papers by Nadya Dimitrova Breakdown of academic impact, for papers by Andrea Krempler Breakdown of academic impact, for papers by Josephine Mun Yee Ko Breakdown of academic impact, for papers by Alex C. Minella
Rankless by CCL
2026